[go: up one dir, main page]

MXPA03010054A - Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos. - Google Patents

Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.

Info

Publication number
MXPA03010054A
MXPA03010054A MXPA03010054A MXPA03010054A MXPA03010054A MX PA03010054 A MXPA03010054 A MX PA03010054A MX PA03010054 A MXPA03010054 A MX PA03010054A MX PA03010054 A MXPA03010054 A MX PA03010054A MX PA03010054 A MXPA03010054 A MX PA03010054A
Authority
MX
Mexico
Prior art keywords
lopinavir
bioavailability
enhancing
compositions
methods
Prior art date
Application number
MXPA03010054A
Other languages
English (en)
Inventor
J Kempf Dale
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MXPA03010054A publication Critical patent/MXPA03010054A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion se refiere a aumentar la biodisponibilidad de agentes farmaceuticamente activos. En particular, esta invencion se refiere al uso de lopinavir, sus equivalentes farmaceuticamente aceptables, y derivados del mismo como inhibidores de glucoproteina P.
MXPA03010054A 2001-05-01 2002-04-29 Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos. MXPA03010054A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36735301P 2001-05-01 2001-05-01
PCT/US2002/013353 WO2002087585A1 (en) 2001-05-01 2002-04-29 Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents

Publications (1)

Publication Number Publication Date
MXPA03010054A true MXPA03010054A (es) 2004-04-02

Family

ID=23446823

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010054A MXPA03010054A (es) 2001-05-01 2002-04-29 Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.

Country Status (10)

Country Link
US (1) US20020198160A1 (es)
EP (1) EP1387684A1 (es)
JP (1) JP2005511481A (es)
AR (1) AR033293A1 (es)
CA (1) CA2445967A1 (es)
MX (1) MXPA03010054A (es)
PE (1) PE20021075A1 (es)
TW (1) TWI231211B (es)
UY (1) UY27275A1 (es)
WO (1) WO2002087585A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
AU2005216712A1 (en) * 2004-01-30 2005-09-09 Pfizer Inc. Compositions comprising HIV protease inhibitor and cytochrome P450 enzyme activity inhibitor
CA2570698C (en) * 2004-06-23 2013-11-19 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
CA2604907A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
MX2008002152A (es) 2005-08-16 2008-04-19 Synta Pharmaceuticals Corp Formulacion de bis(tio-hidrazida amida.
MX2009001877A (es) 2006-08-21 2009-03-02 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
AU2007290490B2 (en) * 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US7645904B2 (en) * 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
US20080181948A1 (en) * 2006-11-15 2008-07-31 Abbott Laboratories Solid pharmaceutical dosage formulations
LT2451445T (lt) 2009-07-06 2019-06-25 Boehringer Ingelheim International Gmbh Bibw2992, jo druskų ir kietų farmacinių kompozicijų, apimančių šį aktyvųjį ingredientą, džiovinimo būdas
US20130289056A1 (en) * 2010-08-26 2013-10-31 Boehringer Ingelheim International Gmbh Methods of administering an egfr inhibitor
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
WO2002087585A1 (en) 2002-11-07
TWI231211B (en) 2005-04-21
EP1387684A1 (en) 2004-02-11
PE20021075A1 (es) 2002-12-07
JP2005511481A (ja) 2005-04-28
UY27275A1 (es) 2002-11-29
CA2445967A1 (en) 2002-11-07
AR033293A1 (es) 2003-12-10
US20020198160A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
UA96449C2 (en) Stable laquinimod preparations
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
DE60332629D1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
AU2003227741A1 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MXPA05002814A (es) Formulacion para agentes lipofilicos.
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUP0300741A3 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
HUP0500574A3 (en) Acridone inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
GB0114286D0 (en) Nucleoside Derivatives
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
IL163831A (en) Derivatives of aminoindazoles, pharmaceutical compositions comprising them, process for their preparation and use thereof
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
PL1687305T3 (pl) Pochodne 1H-imidazochinolin jako inhibitory kinaz białkowych
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MXPA04004567A (es) Compuestos y composiciones de fenoxi amina para adminstrar agentes activos.
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
SE0101932D0 (sv) Pharmaceutical combinations
AU2002358676A1 (en) Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
SE0102440D0 (sv) New compound

Legal Events

Date Code Title Description
FA Abandonment or withdrawal